5-Amino-1MQ is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied for adipose-tissue metabolism, NAD+ preservation, and fat-loss research. It is a quinolinium-based molecule (not a peptide) with unusually high oral bioavailability for this research category.
Standard Research Dosage
Research protocols commonly use 50–150 mg per day taken orally, most often as a single daily dose. Its high membrane permeability allows oral administration to reach intracellular NNMT — unlike most compounds in this space that require injection.
Administration and Timing
5-Amino-1MQ is taken orally, typically in the morning. Because it works by preserving cellular NAD+ and methyl-donor pools rather than by acute stimulation, effects in research models accumulate over days to weeks rather than acutely.
Mechanism of Action
By inhibiting NNMT, 5-Amino-1MQ preserves S-adenosylmethionine (the body's primary methyl donor) and nicotinamide (an NAD+ precursor), shifting adipocyte metabolism toward fat oxidation and supporting NAD+/SIRT1 activity.
Cycle Length
Animal studies showing reversal of diet-induced obesity used dosing over 11+ days to several weeks. No completed human clinical trials exist, so research protocols are extrapolated from preclinical models and typically run in multi-week cycles.